In a purified-protein study, chlorprothixene bound the mSin3B PAH1 domain, with a reported WaterLOGSY Kd of 35 ± 11 µM. This additional binding observation does not establish cellular REST displacement. [1]
Chlorprothixene inhibited growth of DAOY medulloblastoma spheroids in a secondary concentration screen, with a reported IC50 of 9.1 µM after 6 days of incubation. The imaging endpoint combined sphere volume and optical density; it does not by itself demonstrate apoptosis or establish that PAH1 binding caused the effect. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Chlorprothixene binding to the mSin3B PAH1 domain
Biochemical assay · Purified mouse Sin3B PAH1 domain (residues 28–107); GST fusion used for STD and WaterLOGSY screening. [1]
Ligand-observed NMR and protein chemical-shift perturbations supported PAH1 binding. WaterLOGSY titration gave the reported Kd. Binding alone does not establish cellular REST displacement or explain growth inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- HSQC: 100 µM PAH1 with 100 µM or 1 mM ligand; STD/WaterLOGSY screening: 10 µM GST-PAH1 with 400 µM ligand; Kd titration: 1 µM protein and 5–50 µM ligand.
- Method
- NMR at 298 K; phosphate buffer pH 7.2.
- Vehicle
- 5% DMSO for screening/HSQC samples in Methods; dilute Kd titration vehicle fraction not separately specified in Results.
- Reported limits
- No incubation duration, Kd ± definition, independent replicate n or direct cellular target-engagement control is established by the selected reporting.
Methods and source locations
Compound reported in the paper: Chlorprothixene; Compound label in the paper: YN28
Results concern the reported chlorprothixene material from another supplier; they do not validate A10207 lots or establish equivalent activity for salts or the trans isomer.
Figure 1a–c; Results: Evaluation of PAH1 binding affinity; Methods: NMR experiments; SI Figure S2e and Table S1 row 28
Binding to mSin3B PAH1: WaterLOGSY titration; protein 1 µM and ligand 5–50 µM as described in Results. The ± definition and replicate n are not specified in the selected reporting. — Results: Evaluation of PAH1 binding affinity by NMR titration; SI Figure S2e, YN28 (PDF p16)
Protein HSQC chemical-shift changes and ligand-observed NMR signals: HSQC with unbound protein spectrum as reference; complementary ligand-observed assays. No GST-only control is described in the selected NMR methods. — Figure 1a–c, YN28; Results: Evaluation of PAH1 binding affinity; Methods: NMR experiments
DAOY spheroid growth inhibition in the secondary concentration screen
Cell-based study · Human DAOY medulloblastoma spheroids in ultra-low attachment U-bottom plates. [1]
Chlorprothixene reduced spheroid growth in the secondary screen. The reported IC50 concerns an imaging-derived volume-sum endpoint, rather than a direct viability, apoptosis or receptor-antagonism measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- Secondary screen: 1, 3, 10 and 30 µM. IC50 9.1 µM is an endpoint estimate, not a treatment concentration.
- Exposure duration
- Compound addition on day 1; Figure 3 caption reports data after 6 days of incubation.
- Method
- DAOY cells seeded at 1000 cells/100 µL per well; spheroid growth monitored by imaging.
- Vehicle
- Figure 3 labels a 0.3% DMSO control; caption describes compound stocks in 3% DMSO before addition. No recalculated solvent fraction is substituted.
- Reported limits
- IC50 fitting method, IC50 uncertainty, independent biological replicate count and dose-specific vehicle matching are not specified in the selected reporting. Primary-screen concentration is internally inconsistent and is not adopted.
Methods and source locations
Compound reported in the paper: Chlorprothixene; Compound label in the paper: YN28
Results concern the reported chlorprothixene material from another supplier; they do not validate A10207 lots or establish equivalent activity for salts or the trans isomer.
Figure 3b and caption; Results: 3D growth inhibition assays of medulloblastoma; Methods: Cell culture and cancer sphere assay; SI Table S1 row 28
DAOY spheroid growth, scored as volume sum (sphere volume and optical density): Cell3iMager imaging; secondary screen after 6 days of incubation. Exact value is reported in Results, not estimated from the bars. Caption specifies triplicate wells; independent biological replicate n and IC50 uncertainty are not specified. — Results: 3D growth inhibition assays of medulloblastoma, YN28; Figure 3b and caption; Methods: Cell culture and cancer sphere assay